2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Measurable Residual Disease, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Animal Model
PAPER

3507 Chromosome 6q loss cooperates with MYD88L265P to drive lymphoplasmacytic lymphoma and its progression to diffuse large B-cell lymphoma

Filip Garbicz, MD, PhD, Johany Penailillo, PhD2, Senthilkumar Muthiah, PhD3, Tuyet Nguyen4, Tomasz Sewastianik, PhD5, Jimmy Le6, Elisa Mandato, PhD7, Tianfang Ma, PhD8, Eleonora Calabretta, MD, PhD9, Elena Ivanova, PhD10, Aisha Saldanha11, Moataz Noureddine12, Rafael Irizarry, PhD13, Margaret Shipp, MD14, Zachary R Hunter, PhD15, Steven Treon, MD, PhD16, Ruben D. Carrasco, MD17
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
10 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
11 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
12 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
14 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
15 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
16 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
17 Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Background: Waldenström macroglobulinemia (WM) is an indolent non-Hodgkin lymphoma characterized by the MYD88L265P mutation with frequent co-deletion of chromosome 6q. Both lesions can also be found in diffuse large B-cell lymphoma (DLBCL), which can arise through WM transformation. The individual and joint contributions of these lesions to cellular origin and progression of WM remain poorly understood.

Aim: To define the individual and cooperative roles of MYD88L265P and chromosome 6q deletion in B-cell lymphomagenesis, with particular emphasis on the morphologic, immunophenotypic and transcriptional evolution from premalignant stages to overt lymphoma.

Methods: Murine chromosome 10q is highly syntenic to human 6q, enabling conditional lox2272-mediated deletion of most of the genes encompassed by the recurrent human 6q deletion. We generated Cd19Cre/+ mice harboring Myd88L252P/+ (MC, the murine ortholog of human L265P; n=21), 10qΔ/+ (QC, murine equivalent of human chromosome 6q deletion, n=36), or both alterations (MQC, n=21), together with Cre-only controls (C, n=50). Mice were followed longitudinally for lymphoma-free survival. A parallel premalignant cohort (118 scheduled collections at 3, 6, 10, 14 and 18 months) underwent comprehensive gross and histopathologic evaluation of spleen, bone marrow, lymph nodes and peritoneal cavity. Matched single-cell suspensions were analyzed by scRNA-seq with B-cell receptor (BCR) reconstruction (TRUST4), and findings were validated by IHC.

Results: PCR and FISH confirmed a 30.5-Mb interval harboring 162 genes between Hivep2 exon 4 and Prdm1 exon 4 corresponding to human 6q21-6q24.1, in B cells carrying the 10q deletion. An aging cohort was followed for up to 2 years, with symptomatic mice undergoing complete necropsy and histopathologic evaluation. Lymphoma developed in 88% of MQC, 67% of QC and 53% of MC mice, compared with 3% of controls. Lymphoma-free survival differed significantly among mutant strains (log-rank p<0.0001); with median survival of 15.6 months for MQC and 20.1 months for QC, whereas median survival was not reached for MC and controls. Survival was significantly shorter in MQC than in either MC (p=0.0009) or QC (p=0.002) mice. Tumors that developed in 10q-deleted mouse strains were substantially bulkier than those in MC mice, with median spleen weight of 1.55 (MQC) and 0.90 g (QC) versus 0.32 g (MC) and 0.19 g (C) (each versus control p≤0.005; QC versus MC p=0.028). Histologically, spleen, lymph node and bone marrow were infiltrated by lymphoplasmacytic B220− SOX5+ PAX5+ IgM+ cells, accompanied by progressive age-dependent accumulation of lymphoplasmacytic cells in the peritoneal cavity. At later timepoints, a subset of mice developed markedly increased tumor burden with sheets of large, predominantly Ki-67-positive cells, consistent with transformation to DLBCL. In the premalignant cohort, MQC mice exhibited significantly increased spleen weights beginning at 3 months of age despite the absence of symptoms or lymphadenopathy (p=0.010 to 0.028). scRNA-seq identified an early clonal expansion of a B1-like population (Pax5+, Bhlhe41+, Fcrl5+, Cr2low, Fcer2low, Ighdlow), with BCR clonality confirmed by TRUST4. These cells demonstrated reduced expression of multiple candidate tumor suppressor genes within the deleted 10q/6q interval, including Tnfaip3, Foxo3, Sesn1, Bclaf1. The B1-like population selectively expanded in QC and MQC mice, but not in MC or control animals, and was enriched in NF-κB and JAK/STAT signaling programs. Both early- and late-stage lymphomas showed increased expression of therapeutic targets, including Bcl2, Ms4a1, Btk and Hck, supporting future therapeutic studies.

Conclusions: Chromosome 6q/10q loss cooperates with MYD88L265P to accelerate lymphomagenesis, enabling proliferation of a clonally expanding B1-like candidate cell of origin. Importantly, this genetically engineered model faithfully recapitulates the immunophenotype, natural history, and large-cell transformation that are observed in human WM. Since it accurately mirrors the human condition - including the expression of key therapeutic targets - it can serve as a biologically relevant preclinical platform. These mouse models can be useful for dissecting disease pathogenesis and specifically for in vivo investigation of novel targeted therapeutics and immunotherapies in 6qdel-driven B-cell lymphomas, such as LPL and DLBCL.

Filip Garbicz, MD, PhD: No relevant conflicts of interest to declare.